CLINICAL_TRIALS
trial_result
· 2011-11-10
Clinical Trial Update: Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse [Phase 2]
Summary
Phase 2 study of temsirolimus (CCI-779) for ovarian cancer with CA125-only relapse was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hellenic Cooperative Oncology Group | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED